Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Pegylated Exenatine Injection (PB-119) in Drug-naïve T2DM Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, aged 18\~75 years old;~* Confirmed T2DM patients meet the diagnostic criteria for type 2 diabetes published by WHO1999；~* 18.5 kg/m2 \< BMI \< 40.0 kg/m2 at screening;~* 7.5% ≤ HbA1c ≤ 11.0% at screening;~* 7.0% ≤ HbA1c ≤ 10.5% when the random;~* 18.5 kg/m2 \< BMI \< 40.0 kg/m2 during screening and before randomization~Exclusion Criteria:~* T1DM;~* Continuous use of insulin for more than 14 days within 1 year before screening or before randomization；~* Treatment with any dipeptidylpeptidase 4 (DPP-4) inhibitor or glucose-dependent insulin-stimulating peptide (GIP) or/and glucagon-like peptide-1 (GLP-1) receptor agonist prior to screening or randomized prior treatment；~* Screening for any of the following heart diseases within the first 6 months or before randomization；~* Patients whose hypertension was not effectively controlled during screening or before randomization (after resting ≥5 minutes, systolic blood pressure ≥160mmHg and/or diastolic blood pressure ≥100mmHg)；~* Serum amylase or lipase \>3×ULN or those with previous diagnosis of acute/chronic pancreatitis were screened or randomly screened；~* Screening for severe trauma or infection that may affect glycemic control within the first month or before randomization；~* A history or family history of medullary thyroid carcinoma (MTC) or multiple endocrine adenomatosis type 2 (MEN2)；~* Known to be allergic or intolerant to the study drug or metformin；~* Female subjects during pregnancy or lactation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- PB-119 once-weekly-subcutaneous injection (Type: EXPERIMENTAL): PB119 (polyethylene glycol exenatide) is a long-acting GLP-1RA for injection, which will be administered 150μg once-weekly subcutaneously to patients in active drug group for 24 weeks.
- Placebo once-weekly-subcutaneous injection (Type: PLACEBO_COMPARATOR): PB-119 150μg matched placebo which will be used in placebo group for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).